Holen Sie sich die Stockscreener-App
103.71
1.63%
-1.72
Handel nachbörslich:
104.72
1.01
+0.97%
Nuvalent Inc Aktie (NUVL) Neueste Nachrichten
Truist Financial Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $140 - Moomoo
NUVL PE Ratio & Valuation, Is NUVL Overvalued - Intellectia AI
Nuvalent CFO Sells $1.2M in Shares - National Today
Nuvalent (NASDAQ:NUVL) CFO Alexandra Balcom Sells 11,430 Shares - marketbeat.com
Nuvalent (NUVL) CFO sells 11,430 shares after option exercise under 10b5-1 plan - stocktitan.net
[Form 4] Nuvalent, Inc. Insider Trading Activity - stocktitan.net
Wells Fargo Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $116 - Moomoo
Nuvalent Insider Sold Shares Worth $537,943, According to a Recent SEC Filing - marketscreener.com
Nuvalent (NUVL) CDO exercises options, sells 5,500 shares under 10b5-1 plan - stocktitan.net
Goldman Sachs Maintains Nuvalent (NUVL) Buy Recommendation - MSN
Stifel Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $135 - moomoo.com
Price-Driven Insight from (NUVL) for Rule-Based Strategy - Stock Traders Daily
Stifel reiterates Buy rating on Nuvalent stock ahead of ROS1 launch - Investing.com Australia
22,000 Class A shares proposed sale — NUVL (NASDAQ: NUVL) - stocktitan.net
Nuvalent Insider Sold Shares Worth $542,991, According to a Recent SEC Filing - marketscreener.com
Nuvalent (NUVL) CLO exercises 5.5K options, sells 5.5K shares under 10b5-1 - stocktitan.net
Nuvalent Initiated at Overweight by Wells Fargo - Moomoo
Wells Fargo initiates Nuvalent stock with overweight rating on drug potential By Investing.com - in.investing.com
Wells Fargo initiates Nuvalent stock with overweight rating on drug potential - Investing.com Canada
Nuvalent (NASDAQ:NUVL) Earns Overweight Rating from Analysts at Wells Fargo & Company - MarketBeat
Wells Fargo Initiates Nuvalent at Overweight With $116 Price Target - marketscreener.com
Wells Fargo Initiates Nuvalent(NUVL.US) With Buy Rating, Announces Target Price $116 - Moomoo
Wells Fargo initiates coverage of Nuvalent (NUVL) with overweight recommendation - MSN
Upcoming AACR 2026 event announcement sees Nuvalent stock down 1.43% - Traders Union
Weekly Trades: Should I set a stop loss on Nuvalent IncQuarterly Trade Summary & Expert Curated Trade Setups - baoquankhu1.vn
Vanguard disaggregates holdings after realignment; Nuvalent (NUVL) ownership listed as 0 - Stock Titan
Nuvalent (NUVL) CFO sells 25,130 shares in Rule 10b5-1 trades - stocktitan.net
S&P 500 Futures Drop in Premarket Trading; Nuvalent, Figure Tech Solns Lead - Barron's
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), TELA Bio (TELA) and Nuvalent (NUVL) - The Globe and Mail
NUVL (NASDAQ: NUVL) files Form 144 to sell Class A shares via J.P. Morgan - Stock Titan
ALK-Positive NSCLC Pipeline Gains Momentum as 6+ Pharma Companies Advance Next-Generation Therapies | DelveInsight - Barchart.com
Hudson Bay Capital Management LP Acquires Stake in Nuvalent, Inc. - National Today
Hudson Bay Capital Management LP Purchases New Stake in Nuvalent, Inc. $NUVL - MarketBeat
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally - AOL.com
Trend Report: Is Nuvalent Inc in a consolidation phase2026 Retail & Weekly Return Optimization Alerts - baoquankhu1.vn
Aug Catalysts: Is Nuvalent Inc in a consolidation phase2026 Price Swings & Daily Momentum Trading Reports - baoquankhu1.vn
Nuvalent (NUVL) officer Benjamin Lane details stock, options and RSUs in Form 3 - Stock Titan
(NUVL) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
FDA Review of Zidesamtinib Data Might Change The Case For Investing In Nuvalent (NUVL) - Yahoo Finance
Cantor Fitzgerald L. P. Makes New $1.95 Million Investment in Nuvalent, Inc. $NUVL - MarketBeat
Does Nuvalent (NUVL) have the potential to rally 37.26% as Wall Street analysts expect? - MSN
Nuvalent to Present New Preclinical and Clinical Data for Zidesa - GuruFocus
Nuvalent to unveil new ROS1+ NSCLC clinical and preclinical data at AACR 2026 - Traders Union
Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026 - StreetInsider
Vestal Point Sells Nuvalent Shares: Portfolio Impact and Company OutlookNews and Statistics - IndexBox
Nuvalent (NUVL) Gets a Buy from Canaccord Genuity - The Globe and Mail
Nuvalent, Inc. (NASDAQ:NUVL) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally - The Motley Fool
Nuvalent's Chief Scientific Officer Sells Over 35,000 Shares - TradingView
Nuvalent (NUVL) CSO sells 35,104 shares after major option exercises - Stock Titan
Nuvalent, Inc. Holdings Raised by HighVista Strategies LLC - National Today
Nuvalent, Inc. $NUVL Holdings Raised by HighVista Strategies LLC - MarketBeat
Farallon Capital Management LLC Sells 147,000 Shares of Nuvalent, Inc. $NUVL - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Acurx Pharmaceuticals (ACXP) - The Globe and Mail
Braidwell LP Sells 162,894 Shares of Nuvalent, Inc. - National Today
Cantor Fitzgerald L. P. Acquires Shares of 22,500 Nuvalent, Inc. $NUVL - MarketBeat
Nuvalent, Inc. $NUVL Position Increased by Commodore Capital LP - MarketBeat
Braidwell LP Sells 162,894 Shares of Nuvalent, Inc. $NUVL - MarketBeat
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):